Navigation Links
OncoSec Receives ISO 13485 Quality Management System Certification
Date:7/30/2012

SAN DIEGO, July 30, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced it has received notified body certification to the International Organization for Standardization's (ISO) 13485 standard for the "design, development, manufacture, and distribution of electroporation devices." The certification confirms the company's Quality Management System (QMS) and that the company's manufacturing processes are controlled, documented and compliant with the stringent requirements set by the European Union.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

"The ISO certification is a significant accomplishment and an important milestone for OncoSec. Certification affirms that our QMS meets the highest standards and strengthens OncoSec's commitment to product quality and development," said Punit Dhillon, President and CEO. "With this certification in place, OncoSec is now one major step closer to obtaining the CE Marking necessary for commercialization in Europe."

Companies receiving the ISO 13485 certification must demonstrate an ability to provide medical devices and related services that consistently meet customer and regulatory requirements. Achievement of ISO certification offers customers and suppliers an additional level of confidence in the quality and reliability of OncoSec devices, as well as the company's commitment to continuous improvement. OncoSec's review was performed by SGS, a world leader among notified bodies in inspection, verification, testing, and certification.

OncoSec's electroporation device, the OncoSec Medical System (OMS), is currently being used in three on-going clinical trials for the treatment of metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. In addition,
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoSec Announces Issuance of New Patent for Method of Use
2. OncoSec Closes $7.75 Million Public Offering
3. OncoSec to Present at 10th Annual BioPartnering North America
4. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
5. UCSB assistant professor of physics receives US Presidential Science Award
6. First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
7. RIT professor receives National Science Foundation grant to improve on-chip networks with wireless technology
8. Little known pregnancy disease, Hyperemesis Gravidarum, receives awareness with a $20,000 donation from the H.E.R. Foundation to begin Genome Research at UCLA
9. Lupin Receives FDA Approval for Generic LYRICA(R)
10. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
11. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... (PRWEB) March 01, 2015 Market ... agreement for quality market research promotion on Internet. ... research reports worked out by DataGroup Booksellers. , ... Market Publishers Ltd, commented on the recent partnership ... DataGroup Booksellers in our team of publishers. Since ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 Immunovaccine ... made aware of a fraudulent press release disseminated this ... to be from Immunovaccine. This press release states that ... Science, Inc. The press release did not originate ... information contained within the press release. Please note ...
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... for its newly developed Bruton,s tyrosine kinase (BTK) ... completed. The results of these preclinical evaluations have ... Administration. The feedback received from the Agency is ... study. Additional preclinical work is required to begin ...
(Date:2/27/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced ... report to their offering. , Global ... data on Trypsin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
Breaking Biology Technology:Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Immunovaccine Disclaims Hoax Press Release 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2
... COATED PLATE ASSAYS , ... the counting of radioimmunoassays based on coated microtitration plates. The following method ... compare the standard immunoassay microtitration plates with those manufactured by PerkinElmer Life ... procedure is straightforward: , (1) Coat ...
... , ... Dpartement dImmunologie, Laboratoires Fournier S.A., France ... TGF- type I and type II receptors ... type II (TRII) tends to act as the primary receptor. In the ...
... L. Smith1, M.J. Price-Jones 1 , K.T. ... plc., Forest Farm, Whitchurch, Cardiff, CF4 7YT, Wales, UK, 2 PerkinElmer ... , INTRODUCTION ... a multi-detector instrument designed for liquid scintillation (LS) or luminescence detection of samples ...
Cached Biology Technology:Coated Plate Immunoassay on the MicroBeta - eg. TSH - IRMA 2Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 2Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 3Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 4Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 5Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 6Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 7Counting Cytostar-T scintillating microplates on the MicroBeta JET 2Counting Cytostar-T scintillating microplates on the MicroBeta JET 3Counting Cytostar-T scintillating microplates on the MicroBeta JET 4Counting Cytostar-T scintillating microplates on the MicroBeta JET 5
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... Philadelphia, PA, May 2, 2012 Although the ... associated. Individuals with epilepsy are more likely to have ... risk factor for psychosis. It is not known whether ... of psychosis is a risk factor for epilepsy. ...
... Infants born to women who used the anti-HIV drug tenofovir ... not weigh less at birth and are not of shorter ... regimens that do not include tenofovir during pregnancy, according to ... However, at 1 year of age, children born to ...
... to sneak up on a huge dinosaur while it sleeps, crawl ... have felt like a needle going in but giant "flea-like" ... just that. And a few actually lived through the experience, ... these creatures, just announced in Current Biology, a professional ...
Cached Biology News:Evidence of familial vulnerability for epilepsy and psychosis 2Anti-HIV drug use during pregnancy does not affect infant size, birth weight 2Anti-HIV drug use during pregnancy does not affect infant size, birth weight 3Jurassic pain: Giant 'flea-like' insects plagued dinosaurs 165 million years ago 2
... Immulon 2HB ELISA ... provide increased binding affinity for hydrophilic ... bottom works well for reagent injection ... Each strip accomodates ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... positively and negatively supercoiled DNA in presence of ... the effects of supercoiling on transcription in vitro ... , Determining the degree of supercoiling of naturally ... differ in length by only one base-pair ...
... Kit for Kilo-Sequencing is designed to aid ... into the multiple cloning sites (MCS) of ... or phagemid vectors (pUC18/19). The kit is ... the target DNA, thereby progressively moving the ...
Biology Products: